Royalty Pharma plc RPRX

Upcoming catalysts

1. November 27, 2026
   Neladalkib (Nuvalent/GSK; royalty-funded candidate) — FDA PDUFA date (licensee-sponsored)In May 2026, Nuvalent announced the FDA accepted its NDA for neladalkib for filing and granted the application Priority Review with a PDUFA date of November 27, 2026.
2. April 23, 2027
   Deucrictibant (Pharvaris; royalty-funded candidate) — FDA PDUFA date (licensee-sponsored)In July 2026, Pharvaris announced that the FDA accepted its NDA for deucrictibant immediate-release for the on-demand treatment of hereditary angioedema attacks and assigned a PDUFA date of April 23, 2027.

Recent results and decisions

1. submitted Novartis completed regulatory submission for pelabresib in myelofibrosis in the European Union based on the positive Phase 3 MANIFEST-2 study.In October 2026, Novartis announced that the regulatory submission for pelabresib in myelofibrosis was completed in the European Union, based on the positive Phase 3 MANIFEST-2 study. Filing
2. adcomm positive European Medicines Agency's CHMP adopted a positive opinion of Rasonque for metastatic pancreatic adenocarcinoma.In October 2026, Revolution Medicines announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion of Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior sys Filing
3. missed Phase 2 MAXPIRe trial of Niktimvo in idiopathic pulmonary fibrosis did not meet its primary endpoint; Syndax does not plan further development in IPF.In October 2026, Syndax Pharmaceuticals (Syndax) announced that the Phase 2 MAXPIRe trial of Niktimvo in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint. Filing

15 more on record.